Beacon Investment Advisory Services Inc. Has $31.58 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Beacon Investment Advisory Services Inc. lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 8.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 63,763 shares of the medical equipment provider's stock after selling 6,190 shares during the quarter. Intuitive Surgical makes up about 1.5% of Beacon Investment Advisory Services Inc.'s holdings, making the stock its 20th biggest holding. Beacon Investment Advisory Services Inc.'s holdings in Intuitive Surgical were worth $31,580,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. First National Bank of Hutchinson acquired a new position in Intuitive Surgical in the first quarter valued at approximately $734,000. Proficio Capital Partners LLC lifted its position in shares of Intuitive Surgical by 2.9% during the 1st quarter. Proficio Capital Partners LLC now owns 1,872 shares of the medical equipment provider's stock worth $927,000 after buying an additional 52 shares during the last quarter. KLP Kapitalforvaltning AS lifted its position in shares of Intuitive Surgical by 3.0% during the 1st quarter. KLP Kapitalforvaltning AS now owns 123,162 shares of the medical equipment provider's stock worth $60,998,000 after buying an additional 3,600 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in shares of Intuitive Surgical by 4.4% in the 1st quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 335,757 shares of the medical equipment provider's stock valued at $166,290,000 after buying an additional 14,002 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Intuitive Surgical in the 1st quarter valued at $4,543,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Insiders Place Their Bets

In related news, EVP Gary Loeb sold 1,700 shares of the stock in a transaction that occurred on Friday, April 25th. The stock was sold at an average price of $513.18, for a total transaction of $872,406.00. Following the completion of the sale, the executive vice president owned 2,245 shares in the company, valued at $1,152,089.10. This represents a 43.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares in the company, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,998 shares of company stock valued at $2,611,577. Company insiders own 0.70% of the company's stock.

Analyst Ratings Changes

ISRG has been the subject of several research analyst reports. Citigroup restated a "buy" rating and issued a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft cut Intuitive Surgical from a "hold" rating to a "sell" rating and decreased their target price for the company from $515.00 to $440.00 in a research report on Monday, June 9th. Wells Fargo & Company lifted their price target on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research report on Wednesday. Truist Financial increased their price objective on Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Barclays lowered their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $592.05.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded down $13.34 during trading hours on Thursday, hitting $488.61. The stock had a trading volume of 2,604,316 shares, compared to its average volume of 1,810,609. The company has a market capitalization of $175.13 billion, a P/E ratio of 68.15, a P/E/G ratio of 5.32 and a beta of 1.64. The firm's 50-day moving average price is $532.65 and its two-hundred day moving average price is $535.75. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company's revenue was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.78 earnings per share. As a group, analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.